Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and practical service availability across selected European markets.
What this comparison shows
Ketamine and esketamine access differs sharply across Europe. A medicine can be licensed but hard to receive, available privately but not reimbursed, reimbursed only for narrow patient groups, or accessible only through a small number of specialist centres.
The table separates three questions that often get blurred together: whether treatment is legally available, whether public or insurance payment exists, and whether patients can actually find a service that can deliver care.
Psychedelic Therapy Access in Europe
Detailed comparison of ketamine and esketamine licensing, reimbursement status, and patient access across selected European markets.
| Country | Ketamine | Esketamine (Spravato) | ||||
|---|---|---|---|---|---|---|
| Licensed | Reimbursement status | Level of patient access | Licensed | Reimbursement status | Level of patient access | |
| Germany | No | No statutory health insurance coverage; individual reimbursement applications via insurers. | Very limited (individual hospitals). | Yes | Reimbursed; positive HTA outcome (G-BA/IQWiG). | Limited, but expanding. |
| United Kingdom | No | No national reimbursement status or routine NHS funding. | Very limited (private clinics, select NHS trusts). | Yes | Not recommended in England and Wales (NICE); recommended in Scotland (SMC). | Extremely limited in England and Wales; private clinic access available. |
| Netherlands | No | Insurance coverage for clinical support costs. | Limited, but expanding. | Yes | Approved for coverage under basic health insurance (2021). | Very limited (few dozen patients yearly). |
| Czech Republic | No | Some insurance coverage with patient co-payment. | Established clinical access since 2020. | Yes | Exceptional reimbursement for TRD; standard reimbursement approved at end of 2024. | Limited, but expanding with major insurance coverage. |
Germany
Ketamine
No statutory health insurance coverage; individual reimbursement applications via insurers.
Very limited (individual hospitals).
Esketamine (Spravato)
Reimbursed; positive HTA outcome (G-BA/IQWiG).
Limited, but expanding.
United Kingdom
Ketamine
No national reimbursement status or routine NHS funding.
Very limited (private clinics, select NHS trusts).
Esketamine (Spravato)
Not recommended in England and Wales (NICE); recommended in Scotland (SMC).
Extremely limited in England and Wales; private clinic access available.
Netherlands
Ketamine
Insurance coverage for clinical support costs.
Limited, but expanding.
Esketamine (Spravato)
Approved for coverage under basic health insurance (2021).
Very limited (few dozen patients yearly).
Czech Republic
Ketamine
Some insurance coverage with patient co-payment.
Established clinical access since 2020.
Esketamine (Spravato)
Exceptional reimbursement for TRD; standard reimbursement approved at end of 2024.
Limited, but expanding with major insurance coverage.
How to use the comparison
- Licensing status: whether the medicine has a formal legal route into care.
- Reimbursement status: whether public or insurance payment is available, and under what restrictions.
- Practical availability: whether services, sites, trained staff, and referral pathways exist.
- A country can look strong on one layer and weak on another.
Why this matters for future psychedelic therapies
Future psychedelic therapies will face the same split, but with more moving parts. Approval will not automatically answer questions about therapist time, dosing supervision, integration, facility requirements, controlled-substance governance, retreatment, or who pays for non-drug care.
Esketamine is the closest mainstream precedent in many countries because it combines a medicine with supervised administration and monitoring. Ketamine services show another pattern: clinics can create practical access before reimbursement is settled, expanding options for some patients while leaving affordability unresolved.
What this page is useful for
- Spot countries where approval, reimbursement, and site readiness are aligned or misaligned.
- Identify where a future psychedelic therapy may need payment rules for non-drug care.
- Use the table as a starting point before launch planning, referral design, or commissioning work.
Important caveat
Reimbursement conditions and site availability can change quickly. Use this comparison as a structured starting point, then check current national sources before making live planning decisions.
Source
- Blossom reimbursement report figure: ketamine and esketamine access comparison across selected European markets.